Product Highlight - Abstral
• The first sublingual formulation of fentanyl citrate approved for the treatment of Breakthrough Cancer Pain
• Quick dissolution allows for rapid transmucosal absorption of fentanyl
• Can be titrated within the recommended dosing regimen to meet the
analgesic requirements of individual patients
Designed for convenient administration
• Easy to use
Reference: Abstral Package insert_230217
Further information is available in section 4j, New In This Issue and mims.com.
Full prescribing information is available upon request.